Hemofil M. (Monoclonal Purified)
Baxter is committed to serving the needs of people around the world with hemophilia as well as people with immune deficiencies and other chronic diseases. Baxter maintains strong relationships with key communities of patients, such as those with hemophilia, beyond providing products. The company continues to advance hemophilia therapy through improved technologies and provides a range of support services for patients – from education to reimbursement assistance. Baxter employees also devote personal time to local hemophilia chapters, fundraising events, summer camps for patients and other activities. Baxter provides similar support to associations and organizations for patients with Primary Immune Deficiencies and other conditions.
-
Factor VIII (FVIII) for the therapy and prophylaxis of Hemorrhages in Hemophilia A, where patients suffer from FVIII deficiency.
- Hemophilia A is also known as ‘Classic Hemophilia '.
- Availability: 500 I.U.
- Plasma pools NAT tested for HIV-1/2, HAV, HBV, HCV and Parvo B19 nucleic acids.
Print this page 